| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.06. | PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 01.06. | Purple Biotech Ltd.: Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer | 47 | GlobeNewswire (Europe) | 26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs. standard-of-care(SoC)... ► Artikel lesen | |
| 21.05. | Purple Biotech Ltd reports results for the quarter ended in January - Earnings Summary | 3 | Reuters | ||
| 21.05. | Purple Biotech GAAP EPADS of -$0.14 beats by $0.05 | 2 | Seeking Alpha | ||
| 21.05. | PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 21.05. | Purple Biotech Ltd.: Purple Biotech Reports First Quarter 2024 Financial Results | 153 | GlobeNewswire (Europe) | REHOVOT, Israel, May 21, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness... ► Artikel lesen | |
| 25.04. | PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 25.04. | Purple Biotech Ltd.: Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting | 79 | GlobeNewswire (Europe) | Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study REHOVOT, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- Purple... ► Artikel lesen | |
| 28.03. | PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 14.03. | PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 14.03. | Purple Biotech Ltd.: Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology | 371 | GlobeNewswire (Europe) | Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines therapeutic activity to the local tumor micro environment which... ► Artikel lesen | |
| 05.03. | PURPLE BIOTECH LTD. - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| 05.03. | Purple Biotech Ltd.: Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results | 466 | GlobeNewswire (Europe) | REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness... ► Artikel lesen | |
| 05.03. | PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 27.02. | PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 27.02. | Purple Biotech Ltd.: Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024 | 356 | GlobeNewswire (Europe) | NT219 was well tolerated Anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR) REHOVOT, Israel, Feb. 27, 2024 (GLOBE... ► Artikel lesen | |
| 13.02. | PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 13.02. | Purple Biotech Ltd.: Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial | 1 | GlobeNewswire (USA) | ||
| 01.02. | Purple Biotech stock climbs 9% on Phase 2 study update | 3 | Seeking Alpha | ||
| 01.02. | Purple Biotech sets phase 2 dose for cancer drug NT219 | 2 | Investing.com |
Seite:
1 2 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 3.759 |
| NVIDIA | 2.615 |
| TUI | 2.084 |
| GAMESTOP | 1.659 |
| BAYER | 1.554 |
| NEL | 1.491 |
| RHEINMETALL | 1.306 |
| BYD | 1.135 |
| DEUTSCHE LUFTHANSA | 1.011 |
| VOLKSWAGEN | 736 |
| TESLA | 724 |
| CARL ZEISS MEDITEC | 574 |
| BASF | 572 |
| SNOWFLAKE | 559 |
| COMMERZBANK | 550 |
| THYSSENKRUPP | 546 |
| PORSCHE SE | 535 |
| AIXTRON SE | 531 |
| APPLE | 518 |
| DEFI TECHNOLOGIES | 507 |
| SUPER MICRO COMPUTER | 478 |
| DEUTSCHE BANK | 465 |
| CAVENDISH HYDROGEN | 463 |
| MERCEDES-BENZ | 446 |
| ALLIANZ | 432 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
